# name
Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease

# metadata.dc.description.abstract[].value
Insulin resistance precedes dyslipidemia and type 2 diabetes mellitus (T2DM) development. Preclinical evidence suggests that peroxisome proliferator-activated receptor (PPAR) β/δ activators may prevent and treat obesity-induced insulin resistance and T2DM, while clinical trials highlight their potential utility in dyslipidemia. This review summarizes recent mechanistic insights into the antidiabetic effects of PPARβ/δ activators, including their anti-inflammatory actions, their ability to inhibit endoplasmic reticulum (ER) stress and hepatic lipogenesis, and to improve atherogenesis and insulin sensitivity, as well as their capacity to activate pathways that are also stimulated by exercise. Findings from clinical trials are also examined. Dissecting the effects of PPARβ/δ ligands on insulin sensitivity and atherogenesis may provide a basis for the development of therapies for the prevention and treatment of T2DM and cardiovascular disease (CVD).

# metadata.dc.relation.ispartof[].value
Trends in Endocrinology and Metabolism, 2016, vol. 27, num. 5, p. 319-334

# metadata.dc.rights[].value
cc-by-nc-nd (c) Elsevier Current Trends, 2016

# metadata.dc.source[].value
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)

# metadata.dc.title[].value
Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease